Experience of percutaneous FDCT assisted cryoablation in the treatment of metastatic lung lesion

The lungs are the most common site of metastatic disease in patients with malignant tumors. The modern approach to treating lung metastases includes systemic anti-cancer therapy and local control of lesions. Although surgical resection has become the gold standard for patients with oligometastatic disease, many patients are not suitable for surgery due to the location of tumors, risks of developing or worsening respiratory failure, or co-existing conditions. For these patients, percutaneous ablation provides a minimally invasive alternative to surgical resection. One such ablation method is cryoablation, which uses extreme cold to destroy tumor tissue. This method shows promising results for local tumor control and improving patient quality of life. The aim of this study was to analyze the safety and effectiveness of cryoablation for the local control of metastatic lung lesions. Data from 19 patients who underwent cryoablation of 28 lung metastases between 2018 and 2023 were analyzed. The indications for treatment included oligometastatic disease or oligoprogression in the lungs. The study demonstrated that percutaneous cryoablation is a safe and effective method of local control for metastatic lung lesions and represents a promising alternative to surgical resection